Loading viewer...
investor_presentation
Format: PDF investor_presentation
Insmed is a biopharmaceutical company developing and commercializing therapies for serious lung diseases. The company markets ARIKAYCE (amikacin liposome inhalation suspension) for mycobacterium avium complex lung disease and is advancing clinical candidates including brensocatib and TPIP.
investor_presentation
46 Pages
investor_presentation
53 Pages
Central Pattana Public Company
Choice Hotels Radisson Acquisition June 2022
investor_presentationinvestor_presentation
17 Pages
Choice Hotels International
investor_presentation
Comtech Telecommunications